Squamous Cell Carcinoma Of Head And Neck clinical trials

Explore recruiting squamous cell carcinoma of head and neck clinical trials.

Recruiting squamous cell carcinoma of head and neck studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Squamous Cell Carcinoma Of Head And Neck trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EORTC-2014-HNCG: PROLoNg: Pembrolizumab and Radiotherapy for OLigometastatic squamous cell carcinoma of the head and Neck: a randomized phase III study

Italy, Belgium, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase I/II trial of TG4050, an individualised gene therapy, in patients with advanced cancer of the head and neck.

France, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

France, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

EORTC 2120-HNCG: Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck squamous cell carcinoma: a randomized phase II study (Ravina)

Italy, Slovenia, Germany, Netherlands, Belgium, Norway +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Activity and safety of peptide-based immunotherapy in an umbrella window of opportunity phase II study in patients with squamous cell carcinoma of the head and neck.

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Squamous Cell Carcinoma Of Head And Neck trials by city

Squamous Cell Carcinoma Of Head And Neck in Toronto Squamous Cell Carcinoma Of Head And Neck in Vancouver Squamous Cell Carcinoma Of Head And Neck in Montreal Squamous Cell Carcinoma Of Head And Neck in Calgary Squamous Cell Carcinoma Of Head And Neck in Edmonton Squamous Cell Carcinoma Of Head And Neck in Ottawa Squamous Cell Carcinoma Of Head And Neck in Winnipeg Squamous Cell Carcinoma Of Head And Neck in Quebec City Squamous Cell Carcinoma Of Head And Neck in Hamilton Squamous Cell Carcinoma Of Head And Neck in Kitchener Squamous Cell Carcinoma Of Head And Neck in London Squamous Cell Carcinoma Of Head And Neck in Halifax Squamous Cell Carcinoma Of Head And Neck in New York Squamous Cell Carcinoma Of Head And Neck in Los Angeles Squamous Cell Carcinoma Of Head And Neck in Chicago Squamous Cell Carcinoma Of Head And Neck in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease